Starting semaglutide: what TikTok fear posts get right and wrong

What's this video probably claiming?

Based on the caption's "Omggggg I'm scared" framing and the semaglutide hashtag, this is almost certainly a first-dose or early-journey post where the creator is documenting the anxiety of starting a GLP-1 receptor agonist, likely for weight loss. These videos follow a predictable script: nervousness about injecting yourself, fear of side effects you've heard about from other TikTokers, and a vague promise to keep followers updated. The creator probably touches on nausea, the idea that the drug will kill your appetite completely, and maybe some secondhand horror story about "Ozempic face" or hair loss. These posts rack up views because the fear is relatable. Millions of people are in the same position, holding a Wegovy pen and wondering what comes next. That relatability doesn't make the information accurate, though.

What does the science actually show?

Semaglutide is a GLP-1 receptor agonist approved by the FDA for chronic weight management under the brand name Wegovy at 2.4mg weekly. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) followed 1,961 adults over 68 weeks and found mean body weight reduction of 14.9% versus 2.4% for placebo. That is a real and significant effect. Nausea is the most commonly reported adverse event, occurring in about 44% of participants in STEP 1, but it's typically dose-dependent and transient, peaking during the dose escalation phase. Vomiting and diarrhea are also common early on. Serious adverse events like pancreatitis or gallbladder disease are documented but rare. The fear many creators project onto their audience is disproportionate to the actual safety profile for most people who are properly screened.

Where does the social media noise diverge from clinical reality?

TikTok's semaglutide content has a dramatic bias problem. Videos about scary side effects or extreme weight loss get algorithmic traction. Videos about uneventful weekly injections do not. This creates a skewed perception that semaglutide is either a miracle or a nightmare, when the clinical reality is more mundane for most patients. "Ozempic face," for example, went massively viral, but a 2023 analysis in Dermatologic Surgery (Alizadeh et al.) noted this is primarily rapid fat loss affecting facial volume, not a drug-specific skin toxicity, and it occurs with any significant weight loss. Hair thinning (telogen effluvium) is similarly a response to caloric deficit and rapid weight change, not a direct pharmacological effect. Creators rarely explain these distinctions, which means their audiences form inaccurate mental models of what they are actually experiencing.

What should you actually know?

If you are starting semaglutide, the first thing worth knowing is that dose escalation exists for a reason. Standard titration for Wegovy starts at 0.25mg weekly for four weeks before stepping up, specifically to minimize gastrointestinal side effects. Skipping that protocol, which some compounded versions make tempting by offering higher concentrations upfront, increases the likelihood of the nausea that TikTok creators are scared of. Second, weight regain after stopping is real and substantial. Wilding et al. (2022, Diabetes, Obesity and Metabolism) showed participants regained two-thirds of lost weight within one year of discontinuation. This is not a short course of medication. Third, semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2, and that screening conversation needs to happen with a licensed prescriber, not via a TikTok comment section.